Clinical Research Directory
Browse clinical research sites, groups, and studies.
Risk Factors for Adverse Outcomes in Sepsis
Sponsor: Qin Zhang
Summary
This multi-phase prospective study utilized Data-Independent Acquisition proteomics on a nested subset (15 SIC vs. 15 matched sepsis) to map early molecular alterations. Guided by gene-set enrichment evidence of extracellular matrix (ECM) disruption as a pathway-derived biomarker. Admission matrix metalloproteinase-3 was validated in 567 critically ill patients (417 sepsis, 150 non-septic controls) across three hospital campuses.
Official title: Risk Factors for Adverse Outcomes in Sepsis: a Multi-omics Exploration Based on Clinical Cohort Studies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
567
Start Date
2017-06-01
Completion Date
2024-10-14
Last Updated
2026-07-28
Healthy Volunteers
No
Conditions
Interventions
Ulinastatin
Observational exposure. Ulinastatin was administered intravenously based solely on the attending physicians' clinical judgment during routine care, typically at a dosage of 500,000 U, once daily (qd). It was not assigned by a predefined study protocol.
Locations (1)
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China